Business Context and Reporting Period
Acurx Pharmaceuticals, Inc. (ACXP), a Delaware corporation and emerging growth company, filed this Form 8-K on April 15, 2026. The filing reports the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement. The Company is headquartered in Staten Island, NY, and its common stock trades on The Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing details a capital raise transaction with the following specific metrics:
- Gross Proceeds: Approximately $2.5 million.
- Securities Issued:
- 816,068 shares of Common Stock at $3.03 per share.
- Pre-Funded Warrants for up to 9,017 shares at $3.029 per share.
- Series H Common Warrants for up to 1,650,170 shares at an exercise price of $2.78 per share.
- Placement Agent Fees: 6.0% of gross proceeds, capped at $50,000 for legal fees and $15,950 for clearing expenses.
- Use of Proceeds: Working capital and general corporate purposes.
The filing does not provide current revenue, profit, cash flow, margin, or debt figures as this is a transactional report rather than a periodic financial statement.
Material Changes and Transaction Terms
The primary material change is the dilution of existing shareholders due to the issuance of new equity and warrants. Key terms include:
- Lock-up Period: A 15-day restriction on the issuance of Common Stock or equivalents following the closing.
- Variable Rate Transaction Restriction: The Company agreed not to enter into variable rate transactions for one year post-closing, with exceptions for "at-the-market" facilities or equity lines of credit after the lock-up period.
- Ownership Blockers: Holders are restricted from exercising warrants if it results in ownership exceeding 4.99% (or 9.99% at option) of outstanding Common Stock, unless 61 days' prior notice is given to increase the cap to 9.99%.
- Registration Rights: The Company must use commercially reasonable efforts to file a Form S-1 for the resale of Series H Warrant shares within 60 days (or 90 days for a full review).
Outlook, Risks, and Contingencies
Outlook and Management Commentary: The Company intends to utilize the net proceeds for working capital. The offering is expected to close on or about April 16, 2026.
Risks and Contingencies:
- Liquidity Risk: There is no established trading market for the Pre-Funded Warrants or Series H Warrants, and the Company does not intend to list them. Consequently, liquidity for these instruments may be extremely limited.
- Regulatory Risk: The closing is subject to customary conditions, and the resale registration for Series H Warrants is contingent on SEC effectiveness.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and expenses.
- Confirm the effective date of the Form S-1 registration statement for the resale of Series H Warrant shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and indemnification obligations.
- Monitor the Company's cash position to assess the sufficiency of the $2.5 million raise for stated working capital needs.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants or Series H Warrants.